Member Info for Nolupus

You may be right about that ...

They Should be selling some Shares into any News but
Just enough to hedge their contract every 3 months :-)

Awaiting more news from TIM this time :-)

Let's wait and see

scoredagainsteps,

If you are so confident why place an order at 12.75 ??

At 13.5 it's already a great "betting" price, imv

Nothing New here except for "positive discussions", but one would'nt expect IMM to comment on "negative discussions" :-)

The time frame is in line with expectations for the P3, imv

The usual spike Down before NEws is my opinion ...

Rumours about the Incanthera investment ...

Let's wait and see if RNS in the next day or two

Halfbutt ,

Have another half bet on now ....

Gone below the Lanstead figure now So Tim will have to play one of his cards , Imv

Wait and see

Very Few transactions going through in the last week.

My bet is that we will be getting some news in the next week when Tim receives his Landstead payment :-)

Wait and see...

To compare the 2, it's always easier to use the market cap instead of SP, imv

December 2015 market cap was 26.4 million and today we are at 24 million .....

reach4stars,

The statement was about pre trial number 1 , so you should be looking at 88 million shares dec 2015 versus 187 million now....That shows a doubling of the number of shares ..

Best regards

Halfbutt,
Whilst i agree that the SP is at a good betting price, there are a number of issues which are imo a bit "simplistic" in CS7 post :-)
Once cannot say that the results from the non european patients were "absurd "
in comparison to a subgroup within a subgroup :-)
One cannot compare the present SP with the SP before the original trial either as many factors have changed, due to dilution and possible market share. ( rights to the US market have been given over to Avion )
Anyway, awaiting news from France and on the new P3, the volumes are small and volatility is the name of the game for the moment, so Patience patience :-)

Not unusual to have a drop in the SP here before news, this is IMM on Aim :-)

let's wait and see.

Sorry but i can't agree with you about the Incanthera "investment"

I have voiced my opinion on that one for a long time and i still believe that it was a major mistake by Imm to invest that two million into Tim's other company at that time.

Dallo,

We should be getting an RNS on this subject shortly, imv

Last week the merger of Elro into Ureka became effective ....

Yes Indeed a long time buy, but with possible news to come from France in the mean time, imo

But if you read the RNS...."Following recruitment of patients"

Following recruitment of patients (to include US, Europe and elsewhere), it is envisaged that this will be a 52-week trial. Both companies will jointly steer the clinical program

Dallo,
I would suggest that you ask IMM directly, if you have doubts about your interpretation of the RNS
Best regards

Please take note of the last P3 trial where 202 patients were recruted

ClinicalTrials.gov Identifier: NCT02504645
Recruitment Status : Completed
First Posted : July 22, 2015
Results First Posted : April 11, 2019
Last Update Posted : April 11, 2019

Dallo,

What you don't seem to understand is that the treatment time will be set at 52 weeks for patients, not that the trial will last for 52 weeks !

What takes the most time in clinical trials is recruiting patients so depending on the number of participants that need to be enrolled ( my guess is still above 300 ) it could take more than a year from the first patient starting treatment to the last patient starting their treatment ....
My estimate of between 3-4 years is far from disgenous when one has to take into consideration , the setup of the centers and the time to analyse the results.

Best regards

halfbutt,

Everyone to their own trades :-)

Just remember that P3 results won't be for another 3-4 years, imv

Also worth reading , imo

https://www.hopkinsrheumatology.org/2020/01/african-american-ethnicity-associated-with-longer-time-to-lupus-low-disease-activity-state/